Publication Success!

A systematic review and meta-analysis from Sidra Medicine researchers highlights the link between IL-33, obesity and type 2 diabetes

We are delighted to offer our congratulations to Ghalia Missous and Nicholas van Panhuys for their latest publication on the role of Interleukin-33 (IL-33) in obesity and type 2 diabetes (T2D)! 🌍✨

As we continue to face the rising prevalence of obesity and T2D worldwide, innovative research is essential for developing novel interventions. This systematic review and meta-analysis delves into IL-33 – a cytokine that plays a dual role in the body by both regulating inflammation and contributing to the immune system’s response. In recent years, it has been increasingly recognized for its involvement in metabolic diseases like obesity and T2D. Indeed, elevated levels of IL-33 have been linked to chronic low-grade inflammation, a hallmark of obesity and a driving factor in the development of insulin resistance, which underpins T2D.

This latest study, published in August this year in the American Journal of Physiology-Endocrinology and Metabolism, examined IL-33 levels across 18 studies, revealing critical insights, including the need for improved measurement methods to reduce heterogeneity in findings. These results are pivotal for enhancing our understanding of IL-33’s role in disease progression and guiding future research.

🔗 Check out the full study here: Circulating interleukin-33 levels in obesity and type 2 diabetes: A systematic review and meta-analysis | American Journal of Physiology-Endocrinology and Metabolism

Let’s celebrate this important work and encourage further exploration into the potential of IL-33 in combating obesity and T2D! 💡